Clinical trials: Marginal Zone B-Cell Lymphoma
Breast Cancer, Lymphoma
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Filgrastim and stem cell factor may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's…
- Trial name
- NCT00005993
- Testing
- aldesleukin, filgrastim, recombinant human stem cell factor
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma Nonhodgkin
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
To ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular…
- Trial name
- NCT04618081
- Where
- Japan
- Volunteers
- 151 people
- Sponsor
- Celgene
Brain and Central Nervous System Tumors, Lymphoma
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003567
- Testing
- filgrastim, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Marginal Zone Lymphoma
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
This is a prospective single arm phase II study, and the purpose of this study is to evaluate the safety and efficacy of orelabrutinib combined with obinutuzumab a in untreated marginal zone lymphoma.
- Trial name
- NCT06513234
- Testing
- Orelabrutinib and obinutuzumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL)
Tumor Registry of Lymphatic Neoplasia
The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
- Trial name
- TLN-Registry (NCT00889798)
- Volunteers
- 3,795 people
- Sponsor
- iOMEDICO AG
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00612716
- Testing
- busulfan, cyclophosphamide, Stem cell infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Cancer
Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to chronic graft-versus-host disease in patients who…
- Trial name
- NCT00957736
- Testing
- polymorphism analysis, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 252 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT06191887
- Testing
- Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past…
- Conditions
- Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma
- Trial name
- NCT04883437
- Testing
- Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Emory University
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
The primary objective of this study is to evaluate the safety of zanubrutinib (also known as BGB-3111) in chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal…
- Conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
- Trial name
- NCT04116437
- Testing
- Zanubrutinib
- Where
- 24 sites in United States
- Volunteers
- 96 people
- Sponsor
- BeiGene
Leukemia, Lymphoma
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003395
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
MALT Lymphoma
Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma
Single arm phase II study of Chlorambucil in combination with subcutaneous Rituximab followed by maintenance therapy with subcutaneous Rituximab in patients with histologically proven diagnosis of CD20-positive marginal zone…
- Trial name
- NCT01808599
- Testing
- Chlorambucil, Rituximab i.v., Rituximab s.c.
- Where
- 38 sites in France, Italy and 1 more
- Volunteers
- 112 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma
Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
This phase Ib/II trial studies the side effects of acalabrutinib and duvelisib and how well they work in treating patients with indolent non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment…
- Conditions
- Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma
- Trial name
- NCT04836832
- Testing
- Acalabrutinib, Duvelisib
- Sponsor
- Narendranath Epperla
Lymphoma
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Giving chemotherapy drugs, such as melphalan, before an autologous stem cell transplant helps stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392691
- Testing
- ibritumomab tiuxetan, rituximab, melphalan
- Where
- 10 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Swiss Cancer Institute
Leukemia, Lymphoma
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00278161
- Testing
- Pegfilgrastim, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Graft Versus Host Disease, Leukemia
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes
- Trial name
- NCT00003661
- Testing
- anti-thymocyte globulin, busulfan, cyclosporine
- Where
- 17 sites in United States
- Volunteers
- 3 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00425802
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Lymphoma in the Orbit
Imaging techniques have considerably improved over the last decades and ocular adnexal lymphomas (OALs) nowadays can be detected.
- Trial name
- NCT01302912
- Testing
- Lymphoma-Biopsy
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich